Note 1 - Summary of Significant Accounting Policies (Details Textual)	9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Number of Tumor Samples	150,000
Cash and Cash Equivalents, at Carrying Value, Total	$ 25,393,738		$ 28,202,615
Long-term Debt, Total	0
Cash, Uninsured Amount	6,514,611
Accounts Receivable, Allowance for Credit Loss, Current	0		0
Accounts Receivable, after Allowance for Credit Loss, Total	324,708		354,196
Contract with Customer, Liability, Total	495,365		$ 186,951
Research and Development Expense, Total	116,763	$ 234,357
Income Tax Expense (Benefit), Total	0
Unrecognized Tax Benefits, Ending Balance	$ 0